Success Metrics

Clinical Success Rate

66.7%

Based on 6 completed trials

Completion Rate

67%(6/9)

Active Trials

0(0%)

Results Posted

133%(8 trials)

Terminated

3(33%)

Phase Distribution

Ph phase_4

11%

Ph phase_1

22%

Ph phase_3

11%

Ph phase_2

56%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 2Efficacy & side effects

5(55.6%)

Phase 3Large-scale testing

1(11.1%)

Phase 4Post-market surveillance

1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(3)

Detailed Status

Completed6

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (22.2%)

Phase 25 (55.6%)

Phase 31 (11.1%)

Phase 41 (11.1%)

Trials by Status

completed667%

terminated333%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_4

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

NCT04792567

completedphase_3

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144

terminatedphase_2

Clinical Trials (9)

Showing 9 of 9 trials

NCT04792567Phase 4

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Completed

NCT01665144Phase 3

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Completed

NCT01801917Phase 2

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Terminated

NCT02029274Phase 2

Safety and Efficacy of BAF312 in Dermatomyositis

Terminated

NCT01565902Phase 1

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Completed

NCT01904214Phase 1

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Completed

NCT00879658Phase 2

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Completed

NCT01148810Phase 2

Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Terminated

NCT01185821Phase 2

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9